JP2023504748A5 - - Google Patents
Info
- Publication number
- JP2023504748A5 JP2023504748A5 JP2022534224A JP2022534224A JP2023504748A5 JP 2023504748 A5 JP2023504748 A5 JP 2023504748A5 JP 2022534224 A JP2022534224 A JP 2022534224A JP 2022534224 A JP2022534224 A JP 2022534224A JP 2023504748 A5 JP2023504748 A5 JP 2023504748A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- liquid pharmaceutical
- pharmaceutical preparation
- preparation according
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025152037A JP2026009902A (ja) | 2019-12-09 | 2025-09-12 | 抗ｐｄ－ｌ１抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945730P | 2019-12-09 | 2019-12-09 | |
| US62/945,730 | 2019-12-09 | ||
| PCT/US2020/063620 WO2021118930A2 (en) | 2019-12-09 | 2020-12-07 | Anti-pd-l1 antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025152037A Division JP2026009902A (ja) | 2019-12-09 | 2025-09-12 | 抗ｐｄ－ｌ１抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023504748A JP2023504748A (ja) | 2023-02-06 |
| JP2023504748A5 true JP2023504748A5 (https=) | 2023-12-14 |
Family
ID=74206149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534224A Withdrawn JP2023504748A (ja) | 2019-12-09 | 2020-12-07 | 抗ｐｄ－ｌ１抗体製剤 |
| JP2025152037A Pending JP2026009902A (ja) | 2019-12-09 | 2025-09-12 | 抗ｐｄ－ｌ１抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025152037A Pending JP2026009902A (ja) | 2019-12-09 | 2025-09-12 | 抗ｐｄ－ｌ１抗体製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230039268A1 (https=) |
| EP (1) | EP4073120A2 (https=) |
| JP (2) | JP2023504748A (https=) |
| KR (1) | KR20220113414A (https=) |
| CN (1) | CN114787191A (https=) |
| AU (1) | AU2020399619A1 (https=) |
| BR (1) | BR112022011228A2 (https=) |
| CA (1) | CA3158987A1 (https=) |
| CL (2) | CL2022001486A1 (https=) |
| CR (1) | CR20220322A (https=) |
| IL (1) | IL293580A (https=) |
| MX (1) | MX2022006784A (https=) |
| PE (1) | PE20221281A1 (https=) |
| TW (1) | TWI886185B (https=) |
| WO (1) | WO2021118930A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| AU2022417501A1 (en) | 2021-12-22 | 2024-07-04 | Genentech, Inc. | Clinical formulations of anti-tigit antibodies |
| WO2024126750A1 (en) | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Methods for treating cancer |
| EP4676963A1 (en) * | 2023-03-08 | 2026-01-14 | Immunovant Sciences GmbH | High concentration protein formulations with polysorbate excipients and methods of making the same |
| WO2025085404A1 (en) | 2023-10-16 | 2025-04-24 | Genentech, Inc. | Diagnostic and therapeutic methods for treating lung cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| MY175472A (en) * | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| TW202508629A (zh) * | 2017-01-17 | 2025-03-01 | 美商建南德克公司 | 皮下her2抗體調配物 |
-
2020
- 2020-12-07 KR KR1020227021568A patent/KR20220113414A/ko active Pending
- 2020-12-07 CR CR20220322A patent/CR20220322A/es unknown
- 2020-12-07 IL IL293580A patent/IL293580A/en unknown
- 2020-12-07 CA CA3158987A patent/CA3158987A1/en active Pending
- 2020-12-07 US US17/783,229 patent/US20230039268A1/en active Pending
- 2020-12-07 EP EP20845457.9A patent/EP4073120A2/en active Pending
- 2020-12-07 JP JP2022534224A patent/JP2023504748A/ja not_active Withdrawn
- 2020-12-07 WO PCT/US2020/063620 patent/WO2021118930A2/en not_active Ceased
- 2020-12-07 MX MX2022006784A patent/MX2022006784A/es unknown
- 2020-12-07 CN CN202080085014.1A patent/CN114787191A/zh active Pending
- 2020-12-07 AU AU2020399619A patent/AU2020399619A1/en active Pending
- 2020-12-07 BR BR112022011228A patent/BR112022011228A2/pt unknown
- 2020-12-07 PE PE2022001036A patent/PE20221281A1/es unknown
- 2020-12-09 TW TW109143376A patent/TWI886185B/zh active
-
2022
- 2022-06-06 CL CL2022001486A patent/CL2022001486A1/es unknown
-
2023
- 2023-04-20 CL CL2023001140A patent/CL2023001140A1/es unknown
-
2025
- 2025-09-12 JP JP2025152037A patent/JP2026009902A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504748A5 (https=) | ||
| JP2016533335A5 (https=) | ||
| TWI829799B (zh) | 一種TGF-β受體融合蛋白醫藥組成物及其用途 | |
| JP6967515B2 (ja) | Ｐｄ−１抗体 | |
| EP2788379B1 (en) | Pdgf receptor beta binding polypeptides | |
| CN112741804A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| JP2022036932A5 (https=) | ||
| TWI865727B (zh) | 一種抗il-4r抗體醫藥組成物及其用途 | |
| CN115867316B (zh) | 抗pd-1抗体药物组合物及其用途 | |
| CN110732023B (zh) | 一种her2抗体药物组合物及其用途 | |
| ES2699078T3 (es) | Proteínas de unión a antigeno específicas para componente amiloide sérico P | |
| US12565526B2 (en) | Formulations of anti-RSV antibodies and methods of use thereof | |
| CN110960490A (zh) | 一种抗egfr抗体偶联药物组合物及其用途 | |
| CN113507938A (zh) | 包含抗il-5抗体的药物组合物及其用途 | |
| JP2025500483A5 (https=) | ||
| JP2023507795A5 (https=) | ||
| KR20240035835A (ko) | 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용 | |
| CN114805570B (zh) | 一种抗人ace2单克隆抗体及其应用 | |
| JP2022513671A (ja) | Ｃｄ４０抗体医薬品組成物およびその使用 | |
| TW202144005A (zh) | 一種抗ｏｘ４０抗體醫藥組成物及其用途 | |
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| AU2023391877A1 (en) | Recombinant antibody, pharmaceutical composition comprising the same, and uses thereof in treating cancers | |
| TW202241505A (zh) | 抗il-17抗體治療自體免疫性疾病和炎症的方法 | |
| JP2024534853A5 (https=) | ||
| WO2022012428A1 (zh) | 抗pd-1抗体及其稳定制剂 |